Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

NCT04041310 is registered in ClinicalTrials.gov with Nouscom SRL as lead sponsor.

NCT NCT04041310
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04041310 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
Lead sponsor
Nouscom SRL
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 21, 2019
Completion date
October 30, 2026
Enrollment
115 (estimated)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, adult